Beyfortus for respiratory syncytial virus infections

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 13 Aug 2024: Trial registered, NCT06551506
  2. 19 Sep 2024: Trial started, NCT06551506

The trials

NCT06551506: The Immunology and Safety of Maternal RSV Vaccination (ABRYSVO), Infant Nirsevimab (BEYFORTUS) Immunization, or Both Products

State
Completed
Phase
Phase 4
People
181 taking part
Started
19 Sep 2024
Primary completion
5 May 2026
Arms
Group 2
Results
None posted
  1. 13 Aug 2024: Trial registered
  2. 19 Sep 2024: Trial started
  3. 5 May 2026: Trial completed

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.